Anti-vascular endothelial growth factor for proliferative diabetic retinopathy (Q24187858)

title

Anti-vascular endothelial growth factor for proliferative diabetic retinopathy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6995643&resulttype=core&format=json

14 May 2020

1 reference

proliferative diabetic retinopathy

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6995643&resulttype=core&format=json

14 May 2020

Mª José Martínez

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6995643&resulttype=core&format=json

14 May 2020

José Antonio Cordero

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6995643&resulttype=core&format=json

14 May 2020

Jennifer R. Evans

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6995643&resulttype=core&format=json

14 May 2020

author name string

José I Pijoán

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6995643&resulttype=core&format=json

14 May 2020

José A Buil-Calvo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6995643&resulttype=core&format=json

14 May 2020

Arturo J Martí-Carvajal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6995643&resulttype=core&format=json

Cochrane Database of Systematic Reviews

14 May 2020

publication date

24 November 2014

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6995643&resulttype=core&format=json

14 May 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6995643&resulttype=core&format=json

14 May 2020

page(s)

CD008721

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6995643&resulttype=core&format=json

Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy

14 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Structural and functional assessment of macula in patients with high-risk proliferative diabetic retinopathy submitted to panretinal photocoagulation and associated intravitreal bevacizumab injections: a comparative, randomised, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Panretinal photocoagulation versus intravitreal injection retreatment pain in high-risk proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Long-term effects of ranibizumab on diabetic retinopathy severity and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Triamcinolone and bevacizumab as adjunctive therapies to panretinal photocoagulation for proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

A masking device and method to create custom laser exposure patterns for verteporfin photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Manipulating angiogenesis in medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Effect of pregnancy on progression of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Blood pressure control and diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes : the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Prevalence of retinopathy differs with age at onset of diabetes in a population of patients with Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Intravitreal triamcinolone for refractory diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Complications in patients after intravitreal injection of bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Anti-vascular endothelial growth factor for proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

The Effect of Adjunctive Intravitreal Bevacizumab for Preventing Postvitrectomy Hemorrhage in Proliferative Diabetic Retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

INTRAVITREAL BEVACIZUMAB AND PANRETINAL PHOTOCOAGULATION FOR PROLIFERATIVE DIABETIC RETINOPATHY ASSOCIATED WITH VITREOUS HEMORRHAGE

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group

21 January 2018

1 reference

12 December 2020

Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy.

1 reference

12 December 2020

Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group

1 reference

12 December 2020

Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group

1 reference

12 December 2020

Is blood pressure a predictor of the incidence or progression of diabetic retinopathy?

1 reference

12 December 2020

Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial

1 reference

12 December 2020

Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes

1 reference

12 December 2020

Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study

1 reference

12 December 2020

Cigarette smoking and ten-year progression of diabetic retinopathy

1 reference

12 December 2020

Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)

1 reference

12 December 2020

Intravitreal bevacizumab versus panretinal photocoagulation for treatment-naïve proliferative and severe nonproliferative diabetic retinopathy

1 reference

12 December 2020

Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy

1 reference

12 December 2020

Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema

1 reference

12 December 2020

The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years

1 reference

12 December 2020

Intravitreal Avastin as an adjunct in patients with proliferative diabetic retinopathy undergoing pars plana vitrectomy.

1 reference

12 December 2020

Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18.

1 reference

12 December 2020

Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group

1 reference

12 December 2020

Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy

1 reference

12 December 2020

Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group

1 reference

12 December 2020

Ten-year incidence of visual loss in a diabetic population

1 reference

12 December 2020

Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage

1 reference

12 December 2020

Photocoagulation Treatment of Proliferative Diabetic Retinopathy: The Second Report of Diabetic Retinopathy Study Findings

1 reference

12 December 2020

Global data on visual impairment in the year 2002

1 reference

12 December 2020

Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy

1 reference

12 December 2020

Retinopathy in diabetes

1 reference

12 December 2020

Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy.

1 reference

12 December 2020

Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group

1 reference

12 December 2020

Photocoagulation treatment of proliferative diabetic retinopathy: relationship of adverse treatment effects to retinopathy severity. Diabetic retinopathy study report no. 5

1 reference

12 December 2020

Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy: prospective randomized study

1 reference

12 December 2020

What is the prevalence of visual impairment in the general and diabetic populations: are there ethnic and gender differences?

1 reference

12 December 2020

A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema

1 reference

12 December 2020

How to identify randomized controlled trials in MEDLINE: ten years on

1 reference

12 December 2020

New visual acuity charts for clinical research

1 reference

12 December 2020

Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial

1 reference

12 December 2020

Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema

1 reference

12 December 2020

Photocoagulation for Diabetic Macular Edema

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721.PUB2

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD008721.PUB2

2 references

Consolidated OpenCitations Corpus – April 2017

1564338

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6995643&resulttype=core&format=json

14 May 2020

1564338

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6995643&resulttype=core&format=json

14 May 2020

2 references

Consolidated OpenCitations Corpus – April 2017

1564338